Eton Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ETON)

CUSIP: 29772L108

Q1 2024 13F Holders as of 31 Mar 2024

Holder snapshot 7 signals
Share change
+34,910
Put/Call ratio
0%
SEC-reported price per share
$3.75
Number of holders
43
Value change
-$87,277
Number of buys
14
Open additional details 1 more signal available
Number of sells
26
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
28,571,429

Security key

29772L108

Report period

Q1 2024

Institutions

43

Top holders

10

Ownership snapshot

Top reported holders of ETON - Eton Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Opaleye Management Inc.
Disclosed value leader
Opaleye Management Inc.
Comparable rows
0/15
Latest evidence
31 Dec 2023
13F Highest disclosed value: $11,080,905 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Opaleye Management Inc. has the largest disclosed position value at $11.08M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Opaleye Management Inc.'s linked filing trail.
Disclosed position value Top 5
Opaleye Management Inc. $11.08M
VANGUARD GROUP INC $4.5M
Westside Investment Management, Inc. $2.47M
National Philanthropic Trust $2.16M
Acuitas Investments, LLC $2.16M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Opaleye Management Inc.
13F
Company
13F
—
denominator unverified
$11,080,905
2,529,887 shares
— 31 Dec 2023
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$4,501,274
1,027,688 shares
— 31 Dec 2023
Westside Investment Management, Inc.
13F
Company
13F
—
denominator unverified
$2,466,424
563,110 shares
— 31 Dec 2023
National Philanthropic Trust
13F
Company
13F
—
denominator unverified
$2,155,451
492,112 shares
— 31 Dec 2023
Acuitas Investments, LLC
13F
Company
13F
—
denominator unverified
$2,155,197
492,054 shares
— 31 Dec 2023
PARADIGM CAPITAL MANAGEMENT INC/NY
13F
Company
13F
—
denominator unverified
$1,314,000
300,000 shares
— 31 Dec 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
43
Shares
7,182,688
Rows available
43
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders
43
Q1 2024 holders
43
Holder diff
0
Investor Q1 2024 Shares Q1 2024 Shares Share Diff Share Chg % Q1 2024 value Q1 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .